Alkermes Plc ALKS:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 02/25/21 EST
19.44UNCH (UNCH)
Volume
3,802
Close
19.44quote price arrow down-0.44 (-2.21%)
Volume
909,829
52 week range
11.98 - 23.92

...

Loading . . .

KEY STATS

  • Open19.87
  • Day High20.30
  • Day Low19.41
  • Prev Close19.44
  • 52 Week High23.92
  • 52 Week High Date02/10/21
  • 52 Week Low11.98
  • 52 Week Low Date03/18/20
  • Market Cap3.096B
  • Shares Out159.24M
  • 10 Day Average Volume1.49M
  • Dividend-
  • Dividend Yield-
  • Beta0.91
  • 1 Year % Change-2.46

RATIOS/PROFITABILITY

  • EPS (TTM)-0.70
  • P/E (TTM)-27.83
  • Fwd P/E (NTM)64.16
  • EBITDA (MRQ)-30.573M
  • ROE (MRQ)-10.30%
  • Revenue (MRQ)1.039B
  • Gross Margin (MRQ)82.83%
  • Net Margin (MRQ)-10.67%
  • Debt To Equity (MRQ)25.77%

EVENTS

  • Earnings Date04/27/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Alkermes Plc News

There is no recent news for this security.

Latest ALKS News From Our Partners

QUOTE FINDER

Profile

MORE
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA...
Richard Pops
Chairman
Blair Jackson
Chief Operating Officer
Iain Brown
Chief Financial Officer
Craig Hopkinson M.D.
Executive Vice President
Address
Connaught HSE, 1 Burlington Road
Dublin
00000
Ireland